Publications

Exploring Racial Disparities in treatment patterns and outcomes among Patients with Multiple Myeloma using Real World Data →

Maignan, K, Fashoyin-Aje, LA, Torres, AZ, Fernandes, LL, Gwise, T, Baxi, SS, Roose, JP, Rivera, DR, Shen, YL, Kluetz, P, Gormley, NJ

April 2022

Manuscript

Blood Cancer Journal

Flatiron-authored

Racial differences in impacts of high-risk chromosome abnormalities on multiple myeloma progression and survival in a nationwide electronic health record database →

Calip, GS, Ascha, MS, Wang, X, Pierre, A, Maignan, K, Chiu, BCH, Sweiss, K, Patel, PR, Neparidze, N

December 2021

Abstract

American Society of Hematology Annual Meeting

Flatiron-authored

Emulating control arms for cancer clinical trials using external cohorts created from electronic health record-derived real-world data →

Tan, K, Bryan, J, Segal, BD, Bellomo, L, Nussbaum, NC, Tucker, MG, Torres, AZ, Bennette, CS, Capra, WB, Curtis, MD, Miksad, RA

July 2021

Manuscript

Clinical Pharmacology and Therapeutics

Flatiron-authored

Validation analysis of a composite real-world mortality endpoint for patients with cancer in the US →

Zhang, Q, Gossai, A, Monroe, S, Nussbaum, NC, Parrinello, CM

May 2021

Manuscript

Health Services Research

Flatiron-authored

The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies →

Shaw, JL, Nielson, CM, Park, JK, Marongiu, A, Soff, GA

February 2021

Manuscript

European Journal of Haematology

Role of Neutrophil Lymphocyte Ratio [NLR] as a biomarker of frailty and predictor of survival among older adults with Multiple Myeloma →

Giri, S, Costa, LJ, Godby, KN, Bhatia, S, Williams, G, Olszewski, A

December 2020

Abstract

American Society of Hematology Annual Meeting

Redefining the prognostic significance of t(11,14) multiple myeloma →

Giri, S, Costa, LJ, Godby, KN, Bhatia, S, Williams, G

December 2020

Abstract

American Society of Hematology Annual Meeting

Multiple myeloma in the very old: disease characteristics, treatment patterns and outcomes in the real world →

Giri, S, Costa, LJ, Godby, KN, Bhatia, S, Williams, G

December 2020

Abstract

American Society of Hematology Annual Meeting

Real-world use of maintenance therapy and associated outcomes following autologous stem cell transplant in US patients with newly diagnosed multiple myeloma →

Ammann, EM, Lam, A, Fu, Z, Kampfenkel, T, Sharma, M, Tang, W, Lee, C, Kaila, S, He, J

December 2020

Abstract

American Society of Hematology Annual Meeting

Real world data (RWD) treatment (tx) patterns and sequencing of patients with multiple myeloma (MM) →

Gershon, A, Liu, Y, James, S, Williamson, M, Hong, W, Sarsour, K

December 2020

Abstract

American Society of Hematology Annual Meeting

Treatment patterns and outcomes of multiple myeloma (MM) with chromosome translocation (11,14) in United States routine clinical practice →

Atrash, S, Flahavan, EM, Xu, T, Ma, E, Karve, S, Hong, W, Jirau-Lucca, G, Nixon, M, Ailawadhi, S

December 2020

Abstract

American Society of Hematology Annual Meeting

Progression free survival of relapsed or refractory multiple myeloma (RRMM) after failure of three prior lines of therapy in United States real-world practice →

Kim, C, Braunlin, M, Belani, R, Wheeling, JT

December 2020

Abstract

American Society of Hematology Annual Meeting

Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011–2019 oncology clinic electronic health record data →

Braunlin, M, Belani, R, Buchanan, J, Wheeling, JT, Kim, C

October 2020

Manuscript

Leukemia and Lymphoma

Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma →

Durie, BGM, Kumar, S, Usmani, SZ, Nonyane, BAS, Ammann, EM, Lam, A, Kobos, R, Maiese, EM, Facon, T

August 2020

Manuscript

American Journal of Hematology (AJH)

Patient characteristics, treatment patterns, and outcomes in patients with triple-class-refractory multiple myeloma →

Mehra, M, Vogel, M, Valluri, S, Nair, S, Schecter, J, Slowik, R, Jagannath, S, Weisel, K, Usmani, SZ

June 2020

Abstract

Congress of the European Hematology Association

Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents →

Giri, S, Huntington, SF, Wang, R, Zeidan, AM, Podoltsev, NA, Gore, SD, Ma, X, Gross, CP, Davidoff, AJ, Neparidze, N

May 2020

Manuscript

Blood Advances

Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent, and daratumumab →

Mehra, M, Vogel, M, Valluri, S, Nair, S, Schecter, J, Jagannath, S, Weisel, K, Usmani, SZ

May 2020

Abstract

ASCO Annual Meeting

Approximating international myeloma working group uniform response criteria to derive response for multiple myeloma (MM) patients using data from electronic health records (EHR) →

Foster, RB, Tromanhauser, M, Gayer, C, Gonzales, P, Maignan, K, Opong, A, Torres, AZ

December 2019

Abstract

American Society of Hematology Annual Meeting

Flatiron-authored

Trends in the multiple myeloma treatment landscape: a United States analysis of Oscer electronic health record data 2011-2019 →

Braunlin, M, Belani, R, Buchanan, J, Wheeling, JT, Kim, C

December 2019

Abstract

American Society of Hematology Annual Meeting

Evolving real-world treatment patterns in patients with newly-diagnosed multiple myeloma (NDMM) in the United States (U.S.) →

Ailawadhi, S, Romanus, D, Cherepanov, D, Yin, Y, Cheng, M-R, Hari, P

December 2019

Abstract

American Society of Hematology Annual Meeting

Machine learning-based predictive model of 5-year survival in multiple myeloma autologous transplant patients →

Chen, R, Garapati, S, Wu, D, Ko, S, Falk, S, Dierov, D, Stasiw, A, Opong, A

December 2019

Abstract

American Society of Hematology Annual Meeting

Flatiron-authored

Effectiveness of daratumumab in combination with lenalidomide and dexamethasone (DRd) vs. common standard-of-care regimens in patients with non-transplant newly diagnosed multiple myeloma (NDMM) →

Durie, BGM, Kumar, S, Usmani, SZ, Nonyane, BAS, Ammann, EA, Lam, A, Kobos, R, Maiese, EM, Facon, T

December 2019

Abstract

American Society of Hematology Annual Meeting

Patient characteristics, treatments, and transplant frequency in newly-diagnosed (NDMM) multiple myeloma →

Karve, S, Downer, MK, Kamalakar, R, Maher, J, Pauff, J, Maciag, P, Gasparetto, C

June 2019

Abstract

Congress of the European Hematology Association

Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents →

Giri S, Huntington SF, Wang R, Zeidan AM, Podoltsev NA, Gore S, Ma X, Gross CP, Davidoff AJ, Neparidze N

June 2019

Abstract

ASCO Annual Meeting

Overall survival with oral selinexor plus low dose dexamethasone in patients with triple class refractory-multiple myeloma →

Richardson PG, Jagannath S, Chari A, Vogl DT, Dimopoulos MA, Moreau P, Dingli D, Wei LJ, Li L, Tang S, Reichman W, Kauffman MG, Shah JJ, Shacham S, Lonial S.

June 2019

Abstract

ASCO Annual Meeting

Burden of thrombocytopenia in adult cancer patients receiving chemotherapy →

Soff GA, Shaw J, Kilpatrick K, Marongiu A, Park J.

June 2019

Abstract

ASCO Annual Meeting

Development and initial validation of a prognostic score based on structured data from EHRs →

Backenroth D, Haimson JD, Meropol NJ, Baxi SS.

April 2019

Abstract

AACR Annual Meeting

Flatiron-authored

Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States →

McGrath LJ, Hernandez RK, Overman R, Reams D, Liede A, Brookhart MA, O’Donnell E, Leah J

December 2018

Manuscript

Cancer Medicine

The Real-World Frequency of 24-Hour Urine Protein Electrophoresis (UPEP), Serum Free Light Chain (SFLC), and Serum Protein Electrophoresis (SPEP) Testing in Patients with Multiple Myeloma (MM) →

Foster R, Lipitz NG, Torres AZ, Carson K

December 2018

Abstract

Blood Journal

Flatiron-authored

Real-World Disparities in Daratumumab Utilization for Patients with Relapsed or Refractory Multiple Myeloma (MM) →

Maignan K, Backenroth D, McQuarrie NA, Lipitz NG, Williams E, Carson K

December 2018

Abstract

Blood Journal

Flatiron-authored

Dynamic Changes in International Staging System As a Predictor of Survival Outcome in Patients with Advanced Multiple Myeloma →

Hong JL, Crossland V, Galaznik A, Dolin P

December 2018

Abstract

American Society of Hematology Annual Meeting

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM →

Chari A

December 2018

Abstract

Blood Journal

Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies →

Li B, Ren K, Shen L, Hou P, Sun Z, Di Bacco A, Hong JL, Galaznik A, Dash AB, Crossland V, Dolin P, Szalma S

December 2018

Abstract

Blood Journal

Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib and Dexamethasone: An Enhanced Electronic Health Records Database Analysis →

Chari A, Ung B, Tian M, Agarwal A, Parikh K

December 2018

Abstract

Blood Journal

Validation of Clinical vs Algorithmic Definition of Line of Therapy in Multiple Myeloma →

Black J, Ogbu U, Wassner Fritsch E, Byon J, Yi J, Lu M

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Patterns of Bisphosphonate Treatment Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the USA: Observations from Real-World Data →

Kim C, Hernandez RK, Cyprien L, Liede A, Cheng P

August 2018

Manuscript

Supportive Care in Cancer

Maintenance (MT) Treatment (tx) after Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction and Stem Cell Transplant (SCT) in High-Risk (HR) Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Analysis →

Fonseca R, Parikh K, Ung B, Ni Q, Agarwal A

June 2018

Abstract

ASCO Annual Meeting

Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database →

Chari A, Ung A, Abouzaid S, Ni Q, Parikh K, Agarwal A

December 2017

Abstract

American Society of Hematology Annual Meeting

Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT) →

Fonseca R, Parikh K, Ung B, Ni Q, Abouzaid S, Agarwal A

December 2017

Abstract

American Society of Hematology Annual Meeting

Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States →

McGrath L, Hernandez RK, Overman R, Reams D, Liede A, Brookhart A

December 2017

Abstract

American Society of Hematology Annual Meeting

Multiple Myeloma Patients and Risk of Skeletal Related Events – Real-World Evidence in US Oncology Clinics →

Bhatta S, Cyprien L, Fonseca R, Hernandez RK, Kim C

December 2017

Abstract

American Society of Hematology Oncology

Bone Targeting Agent Treatment Patterns Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the United States: Observations from Real-World Data →

Kim C, Hernandez RK, Cheng P, Smith J, Cyprien L, Liede A

December 2016

Abstract

American Society of Hematology Annual Meeting

Real-World Bortezomib Usage Patterns Among Patients with Relapsed/Refractory Multiple Myeloma →

Calkins G, Kohansimeh J, Krishna A, Green R, Curtis MD, Lindberg F, Jaskiw A, Larrabee K, Terry M, Feinstein RN, Plotkin L, Palladino ML, Nicacio L

June 2015

Abstract

EHA Learning Center

Flatiron-authored